stoxline Quote Chart Rank Option Currency Glossary
  
Tharimmune, Inc. (THAR)
3.8  -0.03 (-0.78%)    07-12 11:37
Open: 3.9
High: 3.93
Volume: 9,468
  
Pre. Close: 3.83
Low: 3.7956
Market Cap: 3(M)
Technical analysis
2024-07-12 12:23:19 PM
Short term     
Mid term     
Targets 6-month :  5.05 1-year :  6.2
Resists First :  4.33 Second :  5.3
Pivot price 3.37
Supports First :  2.75 Second :  2.28
MAs MA(5) :  3.64 MA(20) :  3.32
MA(100) :  5.18 MA(250) :  37.36
MACD MACD :  -0.2 Signal :  -0.4
%K %D K(14,3) :  87.1 D(3) :  85.1
RSI RSI(14): 51.4
52-week High :  163.12 Low :  2.75
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ THAR ] has closed below upper band by 10.1%. Bollinger Bands are 26.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.9 - 3.91 3.91 - 3.93
Low: 3.53 - 3.54 3.54 - 3.56
Close: 3.78 - 3.8 3.8 - 3.82
Company Description

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Headline News

Wed, 10 Jul 2024
Tharimmune names industry veteran Haimovitz as strategic advisor - Investing.com

Mon, 10 Jun 2024
Why Tharimmune (THAR) Shares Are Getting Hammered - Benzinga

Mon, 10 Jun 2024
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - AccessWire

Fri, 24 May 2024
Why Is Tharimmune (THAR) Stock Moving Today? - InvestorPlace

Wed, 22 May 2024
Cimpress EVP and CEO sells over $348k in company stock By Investing.com - Investing.com

Wed, 22 May 2024
Why Tharimmune (THAR) Shares Are Moving - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 1.7 (%)
Held by Institutions 0.5 (%)
Shares Short 26 (K)
Shares Short P.Month 1 (K)
Stock Financials
EPS -22.36
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.97
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -83.5 %
Return on Equity (ttm) -173.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.18
PEG Ratio 0
Price to Book value 0.42
Price to Sales 0
Price to Cash Flow -0.45
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android